Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29112479 | 1.00 | ADAM17 (0.37) | ADAM17MPOHRH3MEN1KMT2A | |
| SCHEMBL29681957 | 1.00 | ADAM17 (0.37) | ADAM17MPOHRH3MEN1KMT2A | |
| SCHEMBL29112240 | 1.00 | ADAM17 (0.37) | ADAM17MPOHRH3MEN1KMT2A | |
| SCHEMBL29112363 | 0.92 | MTNR1A (0.34) | MEN1KMT2AGAAMTNR1ACTSB | |
| SCHEMBL24540492 | 0.92 | MTNR1A (0.34) | MEN1KMT2AGAAMTNR1ACTSB | |
| SCHEMBL29682221 | 0.92 | MTNR1A (0.34) | MEN1KMT2AGAAMTNR1ACTSB | |
| SCHEMBL29112365 | 0.92 | MTNR1A (0.34) | MEN1KMT2AGAAMTNR1ACTSB | |
| SCHEMBL24540815 | 0.90 | MTNR1A (0.33) | MEN1KMT2AGAAMTNR1ACTSB | |
| SCHEMBL24540384 | 0.90 | MAPT (0.41) | MEN1KMT2AGAA | |
| SCHEMBL29682042 | 0.90 | MTNR1A (0.33) | MEN1KMT2AGAAMTNR1ACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | SANOFI (FR) | 2024-04-18 | — | — | US | disclosed |
| WO-2022133027-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | TRPM8, TAS2R8, TRPM7 | ADAM17 2249/4885MPO 4536/4885HRH3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.